PNPLA3-I148M是一种新型体,它干扰了两个主要的肝脏甘油三清除途径
David J Sherman1, Lei Liu2, Edward L LaGory2
1Research and Development, Amgen, Thousand Oaks, CA 91320, USA.
Cell reports
|October 5, 2025
概括
这种PNPLA3-I148M变体是脂肪肝疾病的主要遗传风险,它损害了阿波利波蛋白B (ApoB) 和非常低密度脂蛋白 (VLDL) 的分泌. 这通过改变脂质组成而发生,阻碍VLDL的产生和清除.
科学领域:
- 肝病学和遗传学 肝病学和遗传学
- 肝病的分子机制 肝病的分子机制
背景情况:
- 在全球范围内,PNPLA3-I148M变体是脂肪肝疾病的主要遗传风险因素.
- 对于I148M对脂肪肝病的致病性有助的精确分子机制仍然不完全理解.
研究的目的:
- 阐明PNPLA3-I148M变体促进脂肪肝疾病风险的细胞和分子机制.
- 研究I148M对阿波蛋白B (ApoB) 和非常低密度脂蛋白 (VLDL) 分泌和生物发生的影响.
主要方法:
- 使用了人类肝瘤细胞,这些细胞被设计成表达内源性I148M.
- 使用初级肝细胞和小鼠模型进行体内验证.
- 进行了脂质学分析,以分析细胞脂质组成.
- 研究了ABHD5/CGI-58和PNPLA2在调节I148M效应中的作用.
主要成果:
- 这种PNPLA3-I148M变体显著损害了ApoB和VLDL的细胞分泌.
- I148M改变了脂质代谢,从酸丁胆转变为甘油三,减少了膜流动性和VLDL生物发生.
- 过度表达ABHD5/CGI-58在I148M细胞中挽救了ApoB分泌,而CGI-58或PNPLA2敲击模仿了I148M.
- 观察到的效应并不是由于野生类型PNPLA3.3的功能丧失造成的.
结论:
- PNPLA3-I148M作为一种新型变体,加剧脂肪肝疾病的风险.
- I148M通过同时破坏脂解和VLDL分泌途径来阻碍肝脏甘油三清除.
- 这些发现突出了管理与PNPLA3变异相关的脂肪肝疾病的新疗法目标.
相关概念视频
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
477
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
477
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
212
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
212
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
277
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
277
Hepatic Drug Clearance: Role of Transporters
296
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
296
Hepatic Drug Excretion: Influencing Factors
524
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
524
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166


